---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039900"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:55:12.723105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q3 net loss $3.2M ($0.29/shr); cash $44.9M; LP-284 IND cleared, LP-184 dosed first patient

## Summary
- Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.
- Cash, equivalents, and marketable securities $44.9M at Sep 30 vs $55.2M at Dec 31; runway into at least Q3 2025.
- Received FDA IND clearance for LP-284 Phase 1 trial in refractory non-Hodgkin's lymphomas; dosed first patient in LP-184 Phase 1 solid tumor basket trial.
- RADR AI platform surpassed 36B oncology datapoints; new modules for ADC design, BBB permeability prediction, and IO combination therapy.
- Phase 2 Harmonic trial of LP-300 in never-smoker NSCLC expanded to additional U.S. sites and Asia; Dr. Joseph Treat named lead PI.

## SEC filing metadata
- accession: 0001493152-23-039900
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/0001493152-23-039900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039900
- JSON: https://secwatch.observer/filing/0001493152-23-039900.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039900.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/0001493152-23-039900-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.